Form 483 Hits the SweetSpot for Alleged Follow-up Issues Post author:Sam Post published:March 3, 2016 Post category:The GMP Letter The FDA cited a diabetes device data firm for alleged procedural failings in a recent FDA Form 483. Source: The GMP Letter You Might Also Like European Commission Delays MDR for Another Year Due to COVID-19 May 12, 2020 Calls for Urgent Reforms at MHRA Due to Safety Failings August 6, 2020 FDA Warns Devicemakers Over Pen Needles October 4, 2018